Skip to main content

Zimmer Biomet Holdings Value Stock - Dividend - Research Selection

Zimmer

ISIN: US98956P1021 , WKN: 753718

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company\'s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Zimmer Biomet Holdings, Inc. (ZBH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2025-09-08
Zimmer Biomet details growth drivers, new products, and innovation in orthopedics at

Zimmer Biomet to Showcase Foot and Ankle Portfolio at the American Orthopedic Foot and Ankle Society Annual Conference

2025-09-04
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its participation in the American Orthopedic Foot and Ankle Society Annual Conference in Savannah, Ga. From September 10-13, 2025, Zimmer Biomet's wholly owned subsidiary, Paragon 28, will feature a suite of industry-leading foot and ankle products.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

2025-09-03
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 Unpopular Stock That Deserves a Second Chance and 2 That Underwhelm

2025-09-03
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?

2025-09-02
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors

2025-09-02
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors

How Key Advisor Hires at Zimmer Biomet (ZBH) Have Changed Its Investment Story

2025-08-30
Zimmer Biomet Holdings recently announced the appointments of Dr. Jonathan M. Vigdorchik as Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, and Dr. Anand M. Murthi as Chief Medical Advisor for Shoulder, Sports, Extremities, and Trauma. Both advisors bring significant clinical, academic, and device innovation expertise that could directly influence Zimmer Biomet's product pipeline and surgeon engagement strategies. We'll explore how these new appointments,...

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

2025-08-29
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors

2025-08-28
Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors

Should You Add Zimmer Biomet Stock to Your Portfolio Now?

2025-08-28
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.